-+ 0.00%
-+ 0.00%
-+ 0.00%

CG Oncology to present Phase 2 trial results for cretostimogene-gemcitabine combo in NMIBC

PUBT·05/11/2026 20:23:12
Listen to the news
CG Oncology to present Phase 2 trial results for cretostimogene-gemcitabine combo in NMIBC
  • CG Oncology flagged first results from Phase 2 CORE-008 Cohort CX, testing intravesical cretostimogene grenadenorepvec combined with gemcitabine in high-risk non-muscle invasive bladder cancer patients previously exposed to BCG, including BCG-unresponsive disease.
  • Results have not yet been disclosed, with presentations scheduled for May 15-16 at American Urological Association 2026 meeting in Washington.
  • Readout is positioned as an early look at a combination approach in a difficult-to-treat setting, a key area for future clinical development and potential partnering or financing decisions.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CG Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605111615PRIMZONEFULLFEED9717684) on May 11, 2026, and is solely responsible for the information contained therein.